BioChipNet - The informational website on BioChip Technologies

Transgenomic Reports First Quarter 2012 Financial Results

Wed, 09 May 2012 17:48:43 +0200

Teaser:

Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months ended, March 31, 2012, and provided a business update.

Source: Transgenomic

Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's MaterniT21™ PLUS Lab-Developed Test

Wed, 09 May 2012 17:44:56 +0200

Teaser:

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine’s (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). The test detects certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal anomalies.

Beckman Coulter, Inc. Obtains CLIA Certificate, Licensure for Clinical Sequencing

Wed, 09 May 2012 17:35:02 +0200

Teaser:

Beckman Coulter, Inc. has obtained a CLIA Certificate of Registration, along with Massachusetts State Licensure, allowing Beckman Coulter Genomics to begin accepting clinical samples for genetic sequencing – the most technically complex CLIA category – and to provide those results to physicians for their use in treating, diagnosing and preventing disease in patients.

Illumina to Webcast Live Presentations at Upcoming Investment Conferences in May

Sun, 06 May 2012 15:47:24 +0200

Teaser:

Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company’s presentations at two upcoming investment conferences.
Illumina will webcast its presentation at the Robert W. Baird Growth Stock Conference in Chicago, Illinois, on May 9, 2012. The live webcast is scheduled to begin at 2:55 p.m. ET and will feature an overview of the company by Christian Henry, Senior Vice President and General Manager, Genomic Solutions Business, followed by a question and answer session. Illumina will also webcast its presentation at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada on May 16, 2012. The live webcast is scheduled to begin at 8:00 p.m. ET and will feature an overview of the company by Jay Flatley, President and Chief Executive Officer.

Affymetrix and eBioscience Amend Definitive Merger Agreement

Thu, 03 May 2012 15:30:43 +0200

Teaser:

Affymetrix, Inc., (NASDAQ:AFFX) and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience. Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to usual adjustments. The transaction remains subject to customary closing conditions and is now expected to close late in the quarter ending June 30, 2012.

Affymetrix Reports First Quarter 2012 Results

Thu, 03 May 2012 15:15:40 +0200

Teaser:

Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the first quarter of 2012. Total revenue for the quarter was $65.2 million, as compared to total revenue of $73.7 million for the same period of 2011.

Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012

Thu, 03 May 2012 15:09:52 +0200

Teaser:

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $14.9 million for the first quarter of 2012, an increase of 10% compared to revenue of $13.5 million for the first quarter of 2011. First quarter 2012 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 187%, while revenues from the genetic analysis operating segment decreased 14% in the first quarter of 2012 as compared to the prior year period. Net loss for the first quarter of 2012 was $24.5 million, or $0.22 per share, as compared to net loss of $12.7 million, or $0.13 per share for the same period in 2011, reflecting an increase in costs associated primarily with the early commercialization of the Sequenom CMM MaterniT21™ PLUS laboratory developed test (LDT).

Myriad Genetics Reports Record Third Fiscal Quarter 2012 Results

Tue, 01 May 2012 15:43:36 +0200

Teaser:

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 million reported in the third fiscal quarter of 2011. Earnings per diluted share were $0.34, an increase of 10 percent over the same period of the prior year.

CapitalBio Starts to Construct a New Manufacturing Facility and Laboratories in Chengdu, Deep in the Heart of China

Mon, 30 Apr 2012 15:51:37 +0200

Teaser:

CapitalBio Corporation (CapitalBio) held a ground laying ceremony for the inception of construction of the CapitalBio Chengdu (Wenjiang) Complex at Chengdu International Health City. Dr Jing Cheng the CEO of CapitalBio, Jianping Cheng the Deputy Chancellor of Tsinghua University, municipal government leaders and other executives of CapitalBio attended the ceremony.

Beijing Becomes the First City to Provide Free Neonatal Deafness Gene Mutation Screening to All Newborns

Mon, 30 Apr 2012 15:49:54 +0200

Teaser:

In a major health initiative, the Beijing Municipal Government recently announced a neonatal deafness gene-polymorphism screening project, to examine the genetic status of 200,000 newborns in Beijing in 2012. The entire project has a budget of about 30 million USD and will be supported by government purchase. It is thought that this project is the world’s first mass genetic screening of newborn children for genetic predisposition to deafness, and could be a forerunner of other similar projects.

Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform

Thu, 26 Apr 2012 15:53:49 +0200

Teaser:

Luminex Corporation (NASDAQ: LMNX) announced today that it has received CE marking of both the xMAP NeoPlex4 Assay and NeoPlex® System. This unique system revolutionizes the way newborn screening is performed, providing four assays from one blood spot punch, reducing sample requirements and improving laboratory efficiency.

Luminex Corporation Expands Life Science and Biodefense Groups

Tue, 24 Apr 2012 17:18:58 +0200

Teaser:

Luminex Corporation (NASDAQ: LMNX) today announced the expansion of two dedicated groups within its organization: the Life Science and the Biodefense Groups, each with focused initiatives on the development of Luminex technology into these important market segments. While already participating in these markets, further investment in these groups provides additional growth opportunities to build Luminex leadership, advance scientific research and provide solutions for these evolving markets.

Illumina Launches MyGenome(R) App for iPad(R)

Tue, 24 Apr 2012 12:36:07 +0200

Teaser:

Illumina, Inc. (NASDAQ:ILMN) today announced the availability of its MyGenome application for the iPad, available for download on the App Store(SM) for 99 cents. Illumina’s MyGenome app empowers users to explore a real human genome and view reports about important genetic variations through a simple, intuitive, and educational interface for genetic data exploration and learning.

Illumina Reports Financial Results for First Quarter of Fiscal Year 2012

Tue, 24 Apr 2012 12:34:09 +0200

Teaser:

Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the first quarter of 2012, including revenue of $273 million, a 3% decrease compared to $283 million in the first quarter of 2011.

Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration

Mon, 16 Apr 2012 14:45:31 +0200

Teaser:

Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.